BR0016187A - Processo para a preparação de derivados de aril etanol amina tendo propriedades anti-obesidade e anti-diabéticas - Google Patents

Processo para a preparação de derivados de aril etanol amina tendo propriedades anti-obesidade e anti-diabéticas

Info

Publication number
BR0016187A
BR0016187A BR0016187-0A BR0016187A BR0016187A BR 0016187 A BR0016187 A BR 0016187A BR 0016187 A BR0016187 A BR 0016187A BR 0016187 A BR0016187 A BR 0016187A
Authority
BR
Brazil
Prior art keywords
alkyl
methyl
preparation
obesity
hydrogen
Prior art date
Application number
BR0016187-0A
Other languages
English (en)
Other versions
BRPI0016187B1 (pt
Inventor
Ronnie Maxwell Lawrence
Alan Millar
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0016187A publication Critical patent/BR0016187A/pt
Publication of BRPI0016187B1 publication Critical patent/BRPI0016187B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

"PROCESSO PARA A PREPARAçãO DE DERIVADOS DE ARIL ETANOL AMINA TENDO PROPRIEDADES ANTI - OBESIDADE E ANTI DIABéTICAS". Processo para a preparação de um composto de fórmula (IA) ou um seu sal farmaceuticamente aceitável; onde R^ 1^ é um grupo arila, piridila, tiazolila, fenoxi metila, ou pirimidila, opcionalmente substituído com um ou mais substituintes selecionados do grupo consistindo em halogênio, hidroxi, alcoxi C~ 1-6~, alquila C~ 1-6~, hidroxi metila, triflúor metila, -NR^ 6^R^ 6^, e -NHSO~ 2~R^ 6^, onde cada R^ 6^ é independentemente hidrogênio, ou alquila C~ 1-4~; R^ 2^ é hidrogênio ou alquila C~ 1-6~; R^ 3^ é CO~ 2~R^ 7^ onde R^ 7^ é hidrogênio ou alquila C~ 1-6~; R^ 4^ e R^ 5^ são independentemente hidrogênio, alquila C~ 1-6~, ou -CO~ 2~alquila C~ 1-6~; e Y é N ou CH compreendendo a etapa de preparação de uma diamida de fórmula (II) ou um seu sal farmaceuticamente aceitável; onde R^ 1^ é um grupo arila, piridila, tiazolila, fenoxi metila, ou pirimidila, opcionalmente substituído com um ou mais substituintes selecionados do grupo consistindo em halogênio, hidroxi, alcoxi C~ 1-6~, alquila C~ 1-6~, hidroxi metila, triflúor metila, -NR^ 6^R^ 6^, e -NHSO~ 2~R^ 6^, onde cada R^ 6^ é independentemente hidrogênio, ou alquila C^ 1-4~; R^ 2^ é hidrogênio ou alquila C~ 1-6~; R^ 3^ é CO~ 2~R^ 7^ onde R^ 7^ é alquila C~ 1-6~; R^ 4^ e R^ 5^ são independentemente hidrogênio, alquila C~ 1-6~, -CO~ 2~alquila C~ 1-6~; e Y é N ou CH.
BRPI0016187A 1999-12-11 2000-12-08 processo para a preparação de derivados de aril etanol amina tendo propriedades anti-obesidade e anti-diabéticas BRPI0016187B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929297.1A GB9929297D0 (en) 1999-12-11 1999-12-11 Process
PCT/GB2000/004697 WO2001042195A1 (en) 1999-12-11 2000-12-08 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties

Publications (2)

Publication Number Publication Date
BR0016187A true BR0016187A (pt) 2002-08-13
BRPI0016187B1 BRPI0016187B1 (pt) 2016-08-02

Family

ID=10866125

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0016187A BRPI0016187B1 (pt) 1999-12-11 2000-12-08 processo para a preparação de derivados de aril etanol amina tendo propriedades anti-obesidade e anti-diabéticas

Country Status (23)

Country Link
US (1) US6548523B2 (pt)
EP (1) EP1235788B1 (pt)
JP (1) JP4903964B2 (pt)
KR (1) KR100683614B1 (pt)
CN (1) CN1224609C (pt)
AT (1) ATE292110T1 (pt)
AU (1) AU769387B2 (pt)
BR (1) BRPI0016187B1 (pt)
CA (1) CA2394117C (pt)
CZ (1) CZ303143B6 (pt)
DE (1) DE60019157T2 (pt)
ES (1) ES2236020T3 (pt)
GB (1) GB9929297D0 (pt)
HK (1) HK1045988B (pt)
HU (1) HU229043B1 (pt)
IL (1) IL149585A0 (pt)
NO (1) NO323239B1 (pt)
NZ (1) NZ518795A (pt)
PL (1) PL200540B1 (pt)
PT (1) PT1235788E (pt)
TR (1) TR200201528T2 (pt)
WO (1) WO2001042195A1 (pt)
ZA (1) ZA200204585B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230147A1 (de) * 2001-10-09 2004-01-15 Profos Ag Verfahren zur unspezifischen Anreicherung von Bakterienzellen
US7158049B2 (en) * 2003-03-24 2007-01-02 Schlumberger Technology Corporation Wireless communication circuit
US8213085B2 (en) * 2008-01-18 2012-07-03 Visera Technologies Company Limited Image sensor device with high photosensitivity
WO2010118291A2 (en) * 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP2600859A1 (en) 2010-08-03 2013-06-12 Altherx Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
AU2013216864A1 (en) 2012-02-09 2014-09-11 Altherx, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551260A (en) * 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
GB9525121D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
WO1999057098A2 (en) * 1998-05-01 1999-11-11 Abbott Laboratories Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
NZ518795A (en) 2004-02-27
HK1045988B (zh) 2005-07-15
HK1045988A1 (en) 2002-12-20
IL149585A0 (en) 2002-11-10
BRPI0016187B1 (pt) 2016-08-02
US20020198220A1 (en) 2002-12-26
CZ303143B6 (cs) 2012-05-02
NO20022758D0 (no) 2002-06-10
CN1409700A (zh) 2003-04-09
JP2003516383A (ja) 2003-05-13
ATE292110T1 (de) 2005-04-15
CN1224609C (zh) 2005-10-26
ZA200204585B (en) 2003-12-31
ES2236020T3 (es) 2005-07-16
PT1235788E (pt) 2005-08-31
PL356483A1 (en) 2004-06-28
AU769387B2 (en) 2004-01-22
HU229043B1 (hu) 2013-07-29
NO20022758L (no) 2002-07-01
HUP0203640A2 (hu) 2003-02-28
GB9929297D0 (en) 2000-02-02
WO2001042195A1 (en) 2001-06-14
DE60019157D1 (de) 2005-05-04
CZ20022017A3 (cs) 2003-01-15
DE60019157T2 (de) 2006-02-02
JP4903964B2 (ja) 2012-03-28
KR100683614B1 (ko) 2007-02-16
NO323239B1 (no) 2007-02-05
CA2394117A1 (en) 2001-06-14
EP1235788A1 (en) 2002-09-04
US6548523B2 (en) 2003-04-15
TR200201528T2 (tr) 2002-09-23
CA2394117C (en) 2011-10-04
HUP0203640A3 (en) 2003-08-28
KR20020061636A (ko) 2002-07-24
AU2191101A (en) 2001-06-18
EP1235788B1 (en) 2005-03-30
PL200540B1 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
BR0114851A (pt) Derivados de cianopirrolidina
MY114679A (en) Aroyl-piperidine derivatives
BR9808552A (pt) Composto tricìclico ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
EA200000155A2 (ru) 4-фенилпиридиновые производные
BR9806413A (pt) Composto e uso do mesmo
PT96255A (pt) Processo para a preparacao de novos derivados da 1-naftil-piperazina
BR0209252A (pt) Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
BR9909781A (pt) Composto de formula (i), processo para sua preparação, composição farmacêutica compreendendo dito composto, seu uso e método.
BR0016187A (pt) Processo para a preparação de derivados de aril etanol amina tendo propriedades anti-obesidade e anti-diabéticas
DE69809063T2 (de) Aryloxyanilin-derivate
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
RS51126B (sr) Postupak za pripremanje mezilata piperazin derivata
DK0676397T3 (da) Oxypyridinylquinoxalinderivater
NO171786C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
DK0806413T3 (da) 2-substituerede viatmin D3-derivater
MX7122E (es) Procedimiento para la preparacion de derivados de tiometilpiridina
KR960029312A (ko) N-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
BR0014640A (pt) Composto de amida e composição farmacêutica compreendendo dito composto de amida
EP0315434A3 (en) Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same
KR950704252A (ko) N-치환 이미다졸 유도체
BR0013375A (pt) Composições farmacêuticas contendo derivados tiazolidinodiona e processo para sua preparação
KR920012100A (ko) 비스포스폰산 유도체, 이의 제조 및 용도
TW336232B (en) Indol-3-yl propenoic acid derivatives for antagonizing NMDA(N-methyl-D-aspartate) and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: DE ACORDO COM UM EXAME PRELIMINAR, FOI OBSERVADO QUE AS PAGINAS MODIFICADAS ( 5 E 5A ) SEGUNDO O EXAME PRELIMINAR INTERNACIONAL NAO CORRESPONDEM AS PAGINAS DO RELATORIO DESCRITIVO. AINDA, AS PAGINAS 11 E 11A DIZEM RESPEITO AO QUADRO REIVINDICATORIO QUE, POR SUA VEZ, ORIGINALMENTE POSSUIA APENAS 6 PAGINAS. DESTA FORMA, NAO E POSSIVEL REALIZAR O EXAME DO PRESENTE PEDIDO, UMA VEZ QUE NAO E POSSIVEL ESTABELECER AS PAGINAS DO RELATORIO DESCRITIVO E DO QUADRO REIVINDICATORIO A SEREM EXAMINADAS. EM ASSIM SENDO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO, A REQUERENTE DEVERA APRESENTAR O RELATORIO E O QUADRO REIVINDICATORIO ORIGINAL DEVIDAMENTE PAGINADOS. O DEPOSITANTE DEVE SE MANIFESTAR QUA

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]

Free format text: REFERENTE A NOTIFICACAO DO DESPACHO 7.5 PUBLICADO NA RPI 2227 DE 10/09/2013: REPUBLICO A REFERIDA NOTIFICACAO PARA PUBLICIDADE DA JUNTADA DOS DOCUMENTOS ENCAMINHADOS PELO OFICIO 144/2013/COOPI/GADIP/ANVISA DE 23/08/2013.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)